ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2670

Genome-Wide Association Study On the Severity of Joint Destruction in Autoantibody Positive Rheumatoid Arthritis Identifies a Role for Sperm Associated Antigen 16

Rachel Knevel1, Kerstin Klein2, Klaartje Somers3, Caroline Ospelt4, Jeanine J. Houwing-Duistermaat5, Jessica van Nies6, Diederik P.C. de Rooy6, Laura de Bock7, Joris Schonkeren8, Gerrie Stoeken-Rijsbergen6, Jenna Kiridly9, Luis Rodriguez-Rodriguez9, Quinta Helmer5, Piet Sinissen3, Tom W. J. Huizinga1, René E.M. Toes1, Steffen Gay10, Peter K. Gregersen11, Veerle Somers7 and Annette H.M. van der Helm - van Mil8, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP),, Zurich, Switzerland, 3Hasselt University, Biomedical Research Institute, Diepenbeek, Belgium, 4Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, 5Department of Medical Statistics and Bioinformatics, Leiden, Netherlands, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Hasselt University, Biomedical Research Institute, Belgium, 8Leiden University Medical Center, Leiden, Netherlands, 9Feinstein Institute for Medical Research and North Shore–Long Island Jewish Health System, Manhasset, New York, 10Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 11Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Genetic disorders, radiography, rheumatoid arthritis (RA) and severity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome-Wide Association Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recent genome-wide association studies (GWAs) have identified >30 SNPs predisposing to Rheumatoid Arthritis (RA). These variants are helpful in unraveling the pathogenesis of RA. However, most therapeutic strategies target pathways of disease progression. Genetic factors account for a considerable proportion of variance in joint damage, but thus far only a few replicated severity factors are known and no GWAS has been performed. We aimed to increase the understanding of the processes underlying the inter-individual differences in joint damage in anti-citrullinated peptide antibodies (ACPA)-positive RA by performing a 3-staged GWAS on joint damage progression using high-quality radiological data, followed by in vitro and ex vivo studies.

Methods:

Stage 1 was performed on 385 ACPA-positive RA-patients from the NARAC using Illumina HumanHap 550k BeadChips. Stage 2 concerned of 1,567 X-rays of 301 ACPA-positive RA-patients included in a Dutch cohort with 7 years follow-up. In stage 3, 861 X-rays of 742 North-American ACPA-positive RA-patients included in the NDB and Wichita–cohorts were studied. All X-rays were scored using the Sharp-van der Heijde method (ICCs all >0.9). The expression of SPAG16 variants was studied by RT-qPCR using a RA synovium cDNA library and cDNA derived from other RA tissues and fibroblast-like synoviocytes (FLS). Expression levels of MMP1 and MMP3 of FLS before and after stimulation with TNF-α (10 ng/ml) and IL1β (1ng/ml) were evaluated by RT-qPCR and ELISA (cell culture supernatants). Finally serum MMP3 levels were measured in RA patients of stage 2 using ELISA.

Results:

In stage 1, the strongest association was observed for a cluster of SNPs at 2q34, the region of Sperm associated AntiGen16 (SPAG16, P=4.55×10-7, 0.77 fold progression rate per year per minor allele). Independent replication was obtained in stage 2 and 3, again observing a protective effect on damage progression (P=2.16×10-2 and 2.29×10-2 resp.). Apart from its role in spermatozoa, the function of SPAG16 is incompletely known. We detected SPAG16 isoforms in RA tissues and FLS. No relation between expression levels of SPAG16 transcripts in FLS and SPAG16 genotypes could be detected. However, the matrix degrading capacity of FLS may be affected. FLS of patients with the minor allele tended to express less MMP3 mRNA and secreted lower levels of MMP3 (P=2.28×10-2). Also after cytokine stimulation the minor allele was associated with less production of MMP3. Furthermore, RA-patients carrying the minor allele had lower serological levels of MMP3 (P=4.59×10-2) and lower MMP3 levels were associated with less progression of damage (P=3.09×10-3).

Conclusion:

A genetic variant in SPAG16 is associated with less production of MMP3 by FLS and protection against joint damage progression. These findings indicate a new pathway involved in joint damage in ACPA-positive RA.


Disclosure:

R. Knevel,
None;

K. Klein,
None;

K. Somers,
None;

C. Ospelt,
None;

J. J. Houwing-Duistermaat,
None;

J. van Nies,
None;

D. P. C. de Rooy,
None;

L. de Bock,
None;

J. Schonkeren,
None;

G. Stoeken-Rijsbergen,
None;

J. Kiridly,
None;

L. Rodriguez-Rodriguez,
None;

Q. Helmer,
None;

P. Sinissen,
None;

T. W. J. Huizinga,
None;

R. E. M. Toes,
None;

S. Gay,
None;

P. K. Gregersen,
None;

V. Somers,
None;

A. H. M. van der Helm – van Mil,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-association-study-on-the-severity-of-joint-destruction-in-autoantibody-positive-rheumatoid-arthritis-identifies-a-role-for-sperm-associated-antigen-16/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology